Prevalence and Prognostic Significance of Programmed Death-Ligand 1 Expression in Breast Carcinoma Patients from Central India
Abstract
Breast carcinoma remains the most common cancer among women worldwide and a leading cause of cancer-related deaths. In India, both incidence and mortality are steadily rising, with younger women being disproportionately affected. Programmed death-ligand 1 (PD-L1) expression has emerged as a potential biomarker that influences prognosis and treatment response, especially in triple-negative breast cancer (TNBC). However, limited data from India exist regarding its clinicopathological and prognostic significance. To assess the prevalence of PD-L1 expression and its relationship with clinicopathological features and outcomes in invasive ductal carcinoma (IDC) of the breast in Central India. This retrospective observational study analyzed 145 histologically confirmed IDC cases over 20 months. PD-L1 expression was evaluated immunohistochemically using the Combined Positive Score (CPS ≥10 considered positive). Associations with molecular subtypes, clinicopathological parameters, and survival outcomes were analyzed using Chi-square and Kaplan–Meier methods. Overall, 6.9% of cases were PD-L1 positive, with the highest prevalence in TNBC (18.2%). No significant links were found between PD-L1 expression and tumor grade, size, or nodal status. PD-L1-positive patients showed a trend toward poorer overall survival ( P = 0.053), although disease-free survival was not significantly different. PD-L1 expression in breast carcinoma was relatively low but more common in TNBC. Although not statistically significant, PD-L1 positivity indicated a trend toward worse prognosis. Focused testing in aggressive subtypes and standardized evaluation methods are recommended to better determine its clinical role in Indian patients.